Genetic Predisposition to Male Breast Cancer: A Case Series.

Male breast cancer genetic predisposition multigene analysis next generation sequencing

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 11 10 2022
revised: 14 10 2022
accepted: 17 10 2022
entrez: 1 12 2022
pubmed: 2 12 2022
medline: 6 12 2022
Statut: ppublish

Résumé

Male breast cancer (MBC) is a very rare disorder affecting approximately 1 in 833 men. Genetic predisposition is one of the most important risk factors of MBC with BRCA2 being the most commonly mutated gene in males diagnosed with breast cancer. However, a large part of MBC heritability is still unexplained. This study sought to add to the data already available on the genetics of MBC. Our study initially involved comprehensive analysis of BRCA1 and BRCA2, followed by analysis of 43 genes implicated in cancer predisposition in a series of 100 Greek patients diagnosed with MBC between 1995-2015. Pathogenic variants were identified in 13 patients, with BRCA2 being the most commonly affected gene, followed by BRCA1, RAD50, RAD51B, and MSH3. In agreement with previous reports, BRCA2 is the most important genetic factor of MBC predisposition, while the remaining known cancer predisposition genes are each very rarely involved, rendering conclusions as to their cumulative effect difficult to draw.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Male breast cancer (MBC) is a very rare disorder affecting approximately 1 in 833 men. Genetic predisposition is one of the most important risk factors of MBC with BRCA2 being the most commonly mutated gene in males diagnosed with breast cancer. However, a large part of MBC heritability is still unexplained. This study sought to add to the data already available on the genetics of MBC.
MATERIALS AND METHODS METHODS
Our study initially involved comprehensive analysis of BRCA1 and BRCA2, followed by analysis of 43 genes implicated in cancer predisposition in a series of 100 Greek patients diagnosed with MBC between 1995-2015.
RESULTS RESULTS
Pathogenic variants were identified in 13 patients, with BRCA2 being the most commonly affected gene, followed by BRCA1, RAD50, RAD51B, and MSH3.
CONCLUSION CONCLUSIONS
In agreement with previous reports, BRCA2 is the most important genetic factor of MBC predisposition, while the remaining known cancer predisposition genes are each very rarely involved, rendering conclusions as to their cumulative effect difficult to draw.

Identifiants

pubmed: 36456130
pii: 42/12/5795
doi: 10.21873/anticanres.16086
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5795-5801

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Angela Apessos (A)

Genekor Medical S.A, Athens, Greece.

Konstantinos Agiannitopoulos (K)

Genekor Medical S.A, Athens, Greece; kagiannitopoulos@genekor.com.

Georgia Pepe (G)

Genekor Medical S.A, Athens, Greece.

Georgios N Tsaousis (GN)

Genekor Medical S.A, Athens, Greece.

Panagiota Pitta (P)

AlfaLab Genetics and Genomics Center, Athens, Greece.

Chrysanthi Bili (C)

AlfaLab Genetics and Genomics Center, Athens, Greece.

Lina Florentin (L)

AlfaLab Genetics and Genomics Center, Athens, Greece.

Emmanouel Saloustros (E)

Department of Oncology, University Hospital of Larissa, Larissa, Greece.

Eleftherios Kampletsas (E)

Department of Medical, Oncology, University Hospital of Ioannina, Ioannina, Greece.

Dimitrios Tryfonopoulos (D)

Department of Medical Oncology, "Agios Savvas" Anticancer Hospital, Athens, Greece.

Nikolaos Tsoukalas (N)

Medical Oncology Department, 401 General Military Hospital of Athens, Athens, Greece.

Evangelos Bournakis (E)

Oncologic Clinical Trials and Research Clinic, Metropolitan General Hospital, Athens, Greece.

Flora Zagouri (F)

Department of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.

Athanassios Kotsakis (A)

University Hospital of Heraklion, University of Crete, School of Medicine, Heraklion, Greece.

Anna Koumarianou (A)

Hematology Oncology Unit, Fourth Department of Internal Medicine, National & Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.

Ippokratis Korantzis (I)

Oncology Department, Saint Luke Private Hospital, Thessaloniki, Greece.

Ioannis Boukovinas (I)

Oncology Department, BioClinic Thessaloniki, Thessaloniki, Greece.

George Lypas (G)

Department of Genetic Oncology/Medical Oncology, Hygeia Hospital, Athens, Greece.

Georgios Fountzilas (G)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Medical Oncology, German Oncology Center, Limassol, Cyprus.

Vasiliki Michalaki (V)

"ARETAIEIO" Hospital, Athens, Greece.

Spyridon Xynogalos (S)

Department of Medical Oncology, "METAXA" Memorial Piraeus Cancer Hospital, Piraeus, Greece.

Helena Linardou (H)

Fourth Oncology Department and Comprehensive Clinical Trial Center, Metropolitan Hospital, Athens, Greece.

Eirini Papadopoulou (E)

Genekor Medical S.A, Athens, Greece.

George Nasioulas (G)

Genekor Medical S.A, Athens, Greece.

Vassilis Georgoulias (V)

Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH